NSE: PPLPHARMA | BSE: 543635

Mid-range Performer

Download real time

208.28 4.95 (2.43%)

32.35% Fall from 52W High

7.6M NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

27,685.6

Market Cap

High in industry

1.0

Beta 1Year

Average volatility

Piramal Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PPLPHARMA, BSE:543635 Piramal Pharma Ltd.

Search Inside the pdf :

Piramal Pharma Ltd.

29 Jul 2025

208.28

2.43%

Temporary slowdown before a sprint

Buy: Piramal Pharma Ltd.

Target

ICICI Securities Limited

Piramal Pharma’s (Piramal) Q1FY26 result was below our expectations. Performance was impacted due to lack of revenue from a large innovative CDMO (-5.7% YoY) molecule and delay in shipment timing in CHG business (grew 1%).

Piramal Pharma Ltd. is trading below its 200 day SMA of 215.0

Piramal Pharma Ltd.

29 Jul 2025

208.28

2.43%

Near-term weak due to the muted CHG business

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) exhibited lower-than-expected financial performance in 1QFY26. Lower CDMO and complex hospital generics (CHG) sales led to a considerable operating deleverage.

Piramal Pharma Ltd. is trading below its 200 day SMA of 215.0

Piramal Pharma Ltd.

15 May 2025

208.28

2.43%

Operationally, in-line 4Q; FY25 ends on a strong note

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered in-line sales/EBITDA in 4QFY25. However, its earnings were below our estimate due to impairment of certain intangible assets during the quarter.

Piramal Pharma Ltd. is trading below its 200 day SMA of 215.0

Piramal Pharma Ltd.

30 Jan 2025

208.28

2.43%

Piramal Pharma | Q3FY25 Result Update

Buy: Piramal Pharma Ltd.

Target

Edelweiss

CDMO business to drive growth

Piramal Pharma Ltd. is trading below its 200 day SMA of 215.0

Piramal Pharma Ltd.

24 Oct 2024

208.28

2.43%

Operating performance above est.; FY25 guidance intact

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered better-than-expected operational performance in 2QFY25 fueled by superior traction in the CDMO segment (59% of sales). Following earnings deterioration in FY23/FY24, PIRPHARM is exhibiting healthy recovery in 1HFY25.

Piramal Pharma Ltd. is trading above its 150 day SMA of 204.9

Piramal Pharma Ltd.

25 Sep 2024

208.28

2.43%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

Number of FII/FPI investors decreased from 257 to 247 in Jun 2025 qtr

Piramal Pharma Ltd.

25 Sep 2024

208.28

2.43%

Geared to drive robust operating leverage across segments

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

PIRPHARM is well-positioned to offer differentiated services at the product development and commercial manufacturing stage in the CDMO segment.

Piramal Pharma Ltd. is trading above its 150 day SMA of 204.9

Piramal Pharma Ltd.

12 Aug 2024

208.28

2.43%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

Piramal Pharma Ltd. is trading below its 200 day SMA of 215.0

Piramal Pharma Ltd.

28 Jul 2024

208.28

2.43%

Strong orderbook, cost efficiencies boosting a turnaround

Buy: Piramal Pharma Ltd.

Target

ICICI Securities Limited

Piramal Pharma’s Q1FY25 result was driven by better traction in innovative CDMO portfolio (50% of CDMO sales). Q1 is a seasonally weak quarter due to which its margins (10.5% in Q1FY25 vs 20.8% in Q4FY24) are volatile.